Josh Bilenker and Jeff En­gel­man bun­dle a moth­er lode of cash for their stealthy start­up, at­tract­ing a who's who of biotech in­vestors

Josh Bilenker and Jeff En­gel­man won’t be wor­ry­ing about mon­ey for their stealthy start­up any­time soon.

Late last week the pair filed a Form D for their new biotech Tree­line Bio­sciences out­lin­ing a $212 mil­lion raise for their new com­pa­ny — which Bilenker found­ed around the time he eject­ed from his top po­si­tion at Eli Lil­ly’s on­col­o­gy group.

Their plan is to top out the raise at $220 mil­lion, but with Bilenker’s list of mar­quee in­vestors on board for his lat­est cre­ation, that won’t be much of a stretch.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE